Biogen (BIIB) PT Lowered to $343 at Wells Fargo
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $210.65 +0.85%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Wells Fargo analyst Mohit Bansal lowered the price target on Biogen (NASDAQ: BIIB) to $343.00 (from $350.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Galaxy Entertainment Group Ltd (27:HK) (GXYEF) PT Lowered to HK$43.60 at Macquarie
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
